4. Références citées


  1. Koskella B, Brockhurst MA. Bacteria-phage coevolution as a driver of ecological and evolutionary processes in microbial communities. FEMS Microbiol Rev2014 Sep;38(5):916-31.

  2. Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance. Adv Appl Microbiol2010;70:217-48.

  3. Brussow H. What is needed for phage therapy to become a reality in Western medicine? Virology2012 Dec 20;434(2):138-42.

  4. Expert round table on a, re-implementation of bacteriophage t, Sybesma W, Rohde C, Bardy P, Pirnay JP et al. Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy-Part II. Antibiotics (Basel)2018 Apr 23;7(2).

  5. Yarmolinsky MB, Sternberg N. Bacteriophage P1. In: Calendar R, editor. The bacteriophages1998. p. 291-438.

  6. Saad AM, Askora A, Soliman AM, Nariya H, Kawasaki T, Fujie M et al. Full genome sequence of a polyvalent bacteriophage infecting strains of Shigella, Salmonella, and Escherichia. Arch Virol2018 Nov;163(11):3207-10.

  7. Jensen EC, Schrader HS, Rieland B, Thompson TL, Lee KW, Nickerson KW et al. Prevalence of broad-host-range lytic bacteriophages of Sphaerotilus natans, Escherichia coli, and Pseudomonas aeruginosa. Appl Environ Microbiol1998 Feb;64(2):575-80.

  8. Azam AH, Tanji Y. Peculiarities of Staphylococcus aureus phages and their possible application in phage therapy. Appl Microbiol Biotechnol2019 Jun;103(11):4279-89.

  9. Bolocan AS, Callanan J, Forde A, Ross P, Hill C. Phage therapy targeting Escherichia coli-a story with no end? FEMS Microbiol Lett2016 Nov;363(22).

  10. Nobrega FL, Vlot M, de Jonge PA, Dreesens LL, Beaumont HJE, Lavigne R et al. Targeting mechanisms of tailed bacteriophages. Nat Rev Microbiol2018 Dec;16(12):760-73.

  11. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol2013 Jun;8(6):769-83.

  12. Jault P, Leclerc T, Jennes S, Pirnay JP, Que YA, Resch G et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis2019 Jan;19(1):35-45.

  13. Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M et al. The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm Res2011 Apr;28(4):934-7.

  14. Dublanchet A, Fruciano E. [A short history of phage therapy]. Med Mal Infect2008 Aug;38(8):415-20.

  15. Summers WC. The strange history of phage therapy. Bacteriophage2012 Apr 1;2(2):130-33.

  16. Harper DR, McConville M, Anderson FJ, Enright MC. Antimicrobial phages. In: Academic Press L, editor. Molecular Medical Microbiology2015. p. 567-82.

  17. Kanji K, Saatci D, Rao GG, Khanna P, Bassett P, Williams B et al. Antibiotics for tonsillitis: should the emergency department emulate general practice? J Clin Pathol2016 Sep;69(9):834-6.

  18. Pouillot F, Chomton M, Blois H, Courroux C, Noelig J, Bidet P et al. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother2012 Jul;56(7):3568-75.

  19. Skurnik M, Strauch E. Phage therapy: facts and fiction. Int J Med Microbiol2006 Feb;296(1):5-14.

  20. Payne RJ, Jansen VA. Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol2001 Jan 7;208(1):37-48.

  21. Cairns BJ, Timms AR, Jansen VA, Connerton IF, Payne RJ. Quantitative models of in vitro bacteriophage-host dynamics and their application to phage therapy. PLoS Pathog2009 Jan;5(1):e1000253.

  22. Weld RJ, Butts C, Heinemann JA. Models of phage growth and their applicability to phage therapy. J Theor Biol2004 Mar 7;227(1):1-11.

  23. Van Belleghem JD, Dabrowska K, Vaneechoutte M, Barr JJ, Bollyky PL. Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System. Viruses2018 Dec 25;11(1).

  24. Manrique P, Bolduc B, Walk ST, van der Oost J, de Vos WM, Young MJ. Healthy human gut phageome. Proc Natl Acad Sci U S A2016 Sep 13;113(37):10400-5.

  25. Shkoporov AN, Hill C. Bacteriophages of the Human Gut: The "Known Unknown" of the Microbiome. Cell Host Microbe2019 Feb 13;25(2):195-209.

  26. Miernikiewicz P, Dabrowska K, Piotrowicz A, Owczarek B, Wojas-Turek J, Kicielinska J et al. T4 phage and its head surface proteins do not stimulate inflammatory mediator production. PLoS One2013;8(8):e71036. doi: 10.1371/journal.pone.0071036. eCollection 2013.

  27. Van Belleghem JD, Clement F, Merabishvili M, Lavigne R, Vaneechoutte M. Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages. Sci Rep2017 Aug 14;7(1):8004.

  28. Dufour N, Delattre R, Chevallereau A, Ricard JD, Debarbieux L. Phage therapy of pneumonia is not associated with an over stimulation of the inflammatory response compared to antibiotic treatment in mice. Antimicrob Agents Chemother2019 Jun 10.

  29. Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Fortuna W, Letkiewicz S, Szufnarowski K et al. Clinical aspects of phage therapy. Adv Virus Res2012;83:73-121.

  30. Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother2005 Jul;49(7):2874-8.

  31. McCallin S, Alam Sarker S, Barretto C, Sultana S, Berger B, Huq S et al. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology2013 Sep 1;443(2):187-96.

  32. Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health2018;2018(1):60-66.

  33. Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med2019 May;25(5):730-33.

  34. Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S. Compassionate Use of Bacteriophage Therapy for Foot Ulcer Treatment as an Effective Step for Moving Toward Clinical Trials. Methods Mol Biol2018;1693:159-70.

  35. Jennes S, Merabishvili M, Soentjens P, Pang KW, Rose T, Keersebilck E et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. Crit Care2017 Jun 4;21(1):129.

  36. Patey O, McCallin S, Mazure H, Liddle M, Smithyman A, Dublanchet A. Clinical Indications and Compassionate Use of Phage Therapy: Personal Experience and Literature Review with a Focus on Osteoarticular Infections. Viruses2018 Dec 28;11(1).

  37. Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L et al. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother2017 Oct;61(10).

  38. Ochs HD, Buckley RH, Kobayashi RH, Kobayashi AL, Sorensen RU, Douglas SD et al. Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency. Blood1992 Sep 1;80(5):1163-71.

  39. Pyun KH, Ochs HD, Wedgwood RJ, Yang XQ, Heller SR, Reimer CB. Human antibody responses to bacteriophage phi X 174: sequential induction of IgM and IgG subclass antibody. Clin Immunol Immunopathol1989 May;51(2):252-63.

  40. Rubinstein A, Mizrachi Y, Bernstein L, Shliozberg J, Golodner M, Liu GQ et al. Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients. AIDS2000 Mar 10;14(4):F55-62.

  41. Dabrowska K, Miernikiewicz P, Piotrowicz A, Hodyra K, Owczarek B, Lecion D et al. Immunogenicity studies of proteins forming the T4 phage head surface. J Virol2014 Nov;88(21):12551-7.

  42. Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother2007 Aug;51(8):2765-73.

  43. Roach DR, Leung CY, Henry M, Morello E, Singh D, Di Santo JP et al. Synergy between the Host Immune System and Bacteriophage Is Essential for Successful Phage Therapy against an Acute Respiratory Pathogen. Cell Host Microbe2017 Jul 12;22(1):38-47 e4.

  44. Dufour N, Delattre R, Ricard JD, Debarbieux L. The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by beta-Lactams. Clin Infect Dis2017 Jun 1;64(11):1582-88.

  45. Torres-Barcelo C, Hochberg ME. Evolutionary Rationale for Phages as Complements of Antibiotics. Trends Microbiol2016 Apr;24(4):249-56.

  46. Torres-Barcelo C. Phage Therapy Faces Evolutionary Challenges. Viruses2018 Jun 12;10(6).

  47. Torres-Barcelo C, Arias-Sanchez FI, Vasse M, Ramsayer J, Kaltz O, Hochberg ME. A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS One2014;9(9):e106628.

  48. Comeau AM, Tetart F, Trojet SN, Prere MF, Krisch HM. Phage-Antibiotic Synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One2007;2(8):e799.

  49. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM. Therapeutic efficacy of bacteriophage and Baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers. Poult Sci2004 Dec;83(12):1944-7.

  50. Kamal F, Dennis JJ. Burkholderia cepacia complex Phage-Antibiotic Synergy (PAS): antibiotics stimulate lytic phage activity. Appl Environ Microbiol2015 Feb;81(3):1132-8.

  51. Ryan EM, Alkawareek MY, Donnelly RF, Gilmore BF. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol Med Microbiol2012 Jul;65(2):395-8.

  52. Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol2009 Aug;34(4):349-57.

  53. McCallin S, Brüssow H. Clinical Trials of Bacteriophage Therapeutics. In: Harper D, Abedon S, Burrowes B, McConville M, editors. Bacteriophages: Biology, Technology, Therapy. Cham: Springer International Publishing; 2017. p. 1-29.

  54. Sarker SA, Sultana S, Reuteler G, Moine D, Descombes P, Charton F et al. Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. EBioMedicine2016 2016/01/05/;4:124-37.

  55. Sarker SA, Brussow H. From bench to bed and back again: phage therapy of childhood Escherichia coli diarrhea. Ann N Y Acad Sci2016 May;1372(1):42-52.

  56. Rajesh Kannan V, Bastas KK, Rajendran S. Scientific and Economic Impact of Plant Pathogenic Bacteria2015.

  57. Jorgensen PS, Wernli D, Carroll SP, Dunn RR, Harbarth S, Levin SA et al. Use antimicrobials wisely. Nature2016 Sep 8;537(7619):159-61.

  58. Woolhouse M, Ward M, van Bunnik B, Farrar J. Antimicrobial resistance in humans, livestock and the wider environment. Philos Trans R Soc Lond B Biol Sci2015 Jun 5;370(1670):20140083.

  59. Bianchi FJ, Booij CJ, Tscharntke T. Sustainable pest regulation in agricultural landscapes: a review on landscape composition, biodiversity and natural pest control. Proc Biol Sci2006 Jul 22;273(1595):1715-27.

  60. Mallmann W, Hemstreet C. Isolation of an inhibitory substance from plants. Agric Res1924;28:599-602.

  61. Buttimer C, McAuliffe O, Ross RP, Hill C, O'Mahony J, Coffey A. Bacteriophages and Bacterial Plant Diseases. Front Microbiol2017;8:34.

  62. Das M, Bhowmick TS, Ahern SJ, Young R, Gonzalez CF. Control of Pierce's Disease by Phage. PloS One2015 2015;10(6):e0128902.

  63. Zaczek M, Weber-Dabrowska B, Gorski A. Phages in the global fruit and vegetable industry. J Appl Microbiol2015 Mar;118(3):537-56.

  64. Christiansen RH, Dalsgaard I, Middelboe M, Lauritsen AH, Madsen L. Detection and quantification of Flavobacterium psychrophilum-specific bacteriophages in vivo in rainbow trout upon oral administration: implications for disease control in aquaculture. Appl Environ Microbiol2014 Dec;80(24):7683-93.

  65. Wernicki A, Nowaczek A, Urban-Chmiel R. Bacteriophage therapy to combat bacterial infections in poultry. Virol J2017 Sep 16;14(1):179.

  66. Hagens S, Loessner MJ. Phages of Listeria offer novel tools for diagnostics and biocontrol. Front Microbiol2014;5:159.

  67. Carter CD, Parks A, Abuladze T, Li M, Woolston J, Magnone J et al. Bacteriophage cocktail significantly reduces Escherichia coli O157: H7 contamination of lettuce and beef, but does not protect against recontamination. Bacteriophage2012 Jul 1;2(3):178-85.

  68. Del Rio B, Sanchez-Llana E, Redruello B, Magadan AH, Fernandez M, Martin MC et al. Enterococcus faecalis Bacteriophage 156 Is an Effective Biotechnological Tool for Reducing the Presence of Tyramine and Putrescine in an Experimental Cheese Model. Front Microbiol2019;10:566.

  69. Jaomanjaka F, Ballestra P, Dols-lafargue M, Le Marrec C. Expanding the diversity of oenococcal bacteriophages: insights into a novel group based on the integrase sequence. Int J Food Microbiol2013 Sep 2;166(2):331-40.

  70. Ladero V, Gomez-Sordo C, Sanchez-Llana E, Del Rio B, Redruello B, Fernandez M et al. Q69 (an E. faecalis-Infecting Bacteriophage) As a Biocontrol Agent for Reducing Tyramine in Dairy Products. Front Microbiol2016;7:445.

  71. Philippe C, Jaomanjaka F, Claisse O, Laforgue R, Maupeu J, Petrel M et al. A survey of oenophages during wine making reveals a novel group with unusual genomic characteristics. Int J Food Microbiol2017 Sep 18;257:138-47.

  72. Philippe C, Krupovic M, Jaomanjaka F, Claisse O, Petrel M, le Marrec C. Bacteriophage GC1, a Novel Tectivirus Infecting Gluconobacter Cerinus, an Acetic Acid Bacterium Associated with Wine-Making. Viruses2018 Jan 16;10(1).

  73. Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR et al. Quality and safety requirements for sustainable phage therapy products. Pharm Res2015 Jul;32(7):2173-9.

  74. Pirnay JP, Merabishvili M, Van Raemdonck H, De Vos D, Verbeken G. Bacteriophage Production in Compliance with Regulatory Requirements. Methods Mol Biol2018;1693:233-52.